Page 4 - Sciences Ltd News Today

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) saw unusually large options trading activity on Tuesday. Traders acquired 8,333 call options on the company. This represents an increase of 169% compared to the average daily volume of 3,098 call options. Insiders Place Their Bets In other Roivant Sciences news, major shareholder Svf Investments (Uk) Ltd […]

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) was the recipient of some unusual options trading on Tuesday. Investors acquired 8,333 call options on the company. This represents an increase of 169% compared to the average volume of 3,098 call options. Wall Street Analysts Forecast Growth Several research firms recently issued reports on ROIV. JPMorgan […]

Immunovant (NASDAQ:IMVT – Free Report) had its target price raised by HC Wainwright from $47.00 to $51.00 in a research report released on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other equities analysts also recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on […]

Edge Wealth Management LLC reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 23.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 134,528 shares of the company’s stock after selling 41,004 shares during the period. Edge Wealth Management LLC’s holdings […]

Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research note released on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $50.00 price objective on the stock. A number of other research analysts have also recently commented on the stock. UBS Group upped their price […]

Artia Global Partners LP raised its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 422.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 824,363 shares of the company’s stock after acquiring an additional 666,600 shares during the […]

Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective reduced by JPMorgan Chase & Co. from $16.00 to $15.00 in a report issued on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock. Several other research analysts also recently weighed in on ROIV. Truist Financial reissued a buy rating and […]

Roivant Sciences (NASDAQ:ROIV – Get Free Report) and LifeVantage (NASDAQ:LFVN – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk. Risk and Volatility Roivant Sciences has a beta of […]

Immunovant (NASDAQ:IMVT – Free Report) had its target price hoisted by HC Wainwright from $29.00 to $47.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunovant’s Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.55) EPS, FY2024 […]

Immunovant (NASDAQ:IMVT – Free Report) had its price target boosted by HC Wainwright from $29.00 to $47.00 in a research report released on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunovant’s Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.55) EPS, […]